MYE0.F MAXCYTE INC DL-01
- Market cap
- EUR 102M
- P/E
- -
- P/B
- 0.76x
- ROE
- -16.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MYE0.F undervalued?
Graham numberThe Graham number of MAXCYTE INC DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MAXCYTE INC DL-01 fundamental analysis
No fundamental analysis for MAXCYTE INC DL-01 yet.
MAXCYTE INC DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MAXCYTE INC DL-01
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in t…
Full company profileMAXCYTE INC DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MAXCYTE INC DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 33.9M | 44.3M | 41.3M | 38.6M | 33.0M | 36.1M |
| Gross Profit | 30.2M | 39.2M | 36.5M | 31.5M | 26.8M | 29.5M |
| Operating Income | -18.2M | -27.4M | -48.3M | -51.2M | -45.3M | -29.9M |
| EBITDA | - | -24.7M | -43.7M | -46.4M | -40.1M | -25.1M |
| Net Income | -19.1M | -23.6M | -37.9M | -41.1M | -44.6M | -24.5M |
| EPS | -0.19 | -0.23 | -0.36 | -0.39 | -0.42 | -0.24 |
| Balance Sheet | ||||||
| Total Assets | 284M | 287M | 268M | 239M | 203M | 182M |
| Total Liabilities | 21.2M | 32.7M | 36.1M | 33.2M | 31.0M | 31.6M |
| Shareholders' Equity | 263M | 254M | 232M | 206M | 171M | 151M |
| Cash & Short-term Investments | 47.8M | 11.1M | 46.5M | 27.9M | 20.1M | 13.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -10.7M | -14.8M | -21.7M | -27.6M | -34.4M | -24.4M |
| Capital Expenditure | 3.83M | 18.5M | 3.70M | 1.65M | 1.77M | 457K |
| Free Cash Flow | -14.5M | -33.3M | -25.4M | -29.3M | -36.2M | -24.9M |
| Ratios | ||||||
| ROE | -7.3% | -9.3% | -16.3% | -19.9% | -26.0% | -16.2% |
| ROA | -6.7% | -8.2% | -14.1% | -17.1% | -22.0% | -13.4% |
| Net Profit Margin | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% | -67.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MAXCYTE INC DL-01 dividends
MAXCYTE INC DL-01 has not paid dividends in the last 5 fiscal years.
Who owns MAXCYTE INC DL-01
- Insiders 1.84%
- Institutions 65.83%
- Public & others 32.34%
- Shares outstanding 103M
- Free float 93.7M
MAXCYTE INC DL-01 company profile
- Company name
- MAXCYTE INC DL-01
- Ticker
- MYE0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 91
- Fiscal year end
- December
- Address
- 9713 Key West Avenue, Rockville, MD, United States, 20850
- Phone
- 301 944 1700
- Website
- maxcyte.com
About MAXCYTE INC DL-01
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MAXCYTE INC DL-01 management
6- Mr. Maher MasoudPresident, CEO & Executive Director · born 1976
- Mr. Parmeet AhujaChief Financial Officer · born 1969
- Mr. Jay GelfmanChief Operations Officer
- Ms. Ana-Paula Martins FernandesSenior Vice President of Global Sales
- Mr. Sidharth KapileshwarChief Corporate Development Officer
- Ms. Jill MayerSenior Vice President of Human Resources